ArticleJournal of inflammation research2025
Integration of Delta-Radiomics Features and Inflammatory Biomarkers for Neoadjuvant Chemo-Immunotherapy Efficacy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Neoadjuvant chemo-immunotherapy (NACI) significantly increases the pathological complete response (pCR) rate in locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, not all patients benefit from this approach. This study aims to construct a multi-omics model for predicting the efficacy of NACI in LA-ESCC patients by integrating delta-radiomics features (delta-RFs) and the dynamic changes in inflammatory biomarkers. Patients and Methods: Our study was the first to develop a multi-omics model based on dynamic CT imaging features and inflammatory indices in patients with LA-ESCC. A total of 217 patients were divided into training (n = 152) and validation (n = 65) cohorts. Following the completion of the data standardization process, delta-RFs were extracted using the PyRadiomics, representing the relative imaging changes between pre- and post-treatment. The algorithm known as the least absolute shrinkage and selection operator (LASSO) was selected to pinpoint the most significant RFs for predicting pCR. The imaging signatures and clinical characteristics were integrated by the logistic regression analysis. Finally, a nomogram was constructed based on the identified independent predictors. Results: The pCR rates were approximately 30% among the enrolled patients. A total of 1834 delta-RFs were extracted. The 12 delta-RFs signature was determined by the optimal regularization parameter using the LASSO algorithm. Furthermore, multivariate regression analyses confirmed that tumor length, delta-RFs signature, and delta-systemic immune-inflammation index (SII) served as independent predictors for pCR prediction. Finally, a nomogram was constructed and the multi-omics model exhibited impressive predictive performance, with area under curve (AUC) values of 0.853 and 0.796 for the training and validation cohorts, respectively. This method aims to support informed treatment decisions and facilitate the development of personalized treatment strategies. Conclusion: The multi-omics model, which is based on the delta-RFs signature and delta-SII indicators prior to surgery, effectively predicts the NACI treatment response in patients with LA-ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.